Latest stories on MPLT
BMO cuts MapLight Therapeutics price target on trial results
Investing.com Analyst Ratings34 · bearishanalyst
Canaccord cuts MapLight Therapeutics stock price target on trial data
Investing.com Analyst Ratings38 · neutralanalyst
H.C. Wainwright cuts MapLight Therapeutics stock price target on trial results
Investing.com Analyst Ratings38 · neutralanalyst
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia - Slideshow
Seeking Alpha50 · neutralgeneral
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
Stocktwits News19 · bearishearnings
Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results
Investing.com Analyst Ratings34 · bearishanalyst
Wolfe cuts MapLight Therapeutics stock price target on trial data
Investing.com Analyst Ratings38 · neutralanalyst
MapLight Therapeutics' Lead Candidate Falls Meaningfully Short In Schizophrenia
Seeking Alpha22 · bearishproduct/pr
MPLT’s ZEPHYR Study Shows Statistically Significant Gains in Schizophrenia—Strong Cognitive Benefit Emerges
July 27, 2026
MarketChameleon73 · bullishproduct/pr
Jefferies reiterates MapLight Therapeutics stock rating on trial data
Investing.com Analyst Ratings56 · neutralanalyst
Raymond James cuts MapLight Therapeutics stock price target on efficacy data
Investing.com Analyst Ratings38 · neutralanalyst
BMO reiterates Outperform on MapLight stock after trial data
Investing.com Analyst Ratings63 · neutralanalyst
MapLight's schizophrenia drug fails once-daily test, shares plunge
Reuters22 · bearishproduct/pr
Stifel reiterates MapLight Therapeutics stock rating on schizophrenia data
Investing.com Analyst Ratings56 · neutralanalyst
MapLight’s ML-007C-MA Demonstrates Statistically Significant Improvements in Schizophrenia Symptoms and Cognition in Phase 2 ZEPHYR Trial
MarketChameleon73 · bullishproduct/pr
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data
Seeking Alpha34 · bearishproduct/pr
MapLight Therapeutics stock tumbles 40% on trial results
Investing.com Markets32 · bearishearnings
MapLight Therapeutics, Inc. (MPLT) files 8-K
SEC 8-K50 · neutralgeneral
UBS raises MapLight Therapeutics stock price target on trial data
Investing.com Analyst Ratings63 · neutralanalyst
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
Yahoo Top67 · bullishanalyst
MapLight Therapeutics: The Cobenfy Challenger Does Not Look Like A Bargain
Seeking Alpha48 · neutralproduct/pr
Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts
Seeking Alpha67 · bullishanalyst
MapLight Therapeutics, Inc. (MPLT) files 8-K
SEC 8-K50 · neutralgeneral
MapLight Therapeutics Announces Changes to Board of Directors | MPLT Stock News
StockTitan50 · neutralgeneral